loader
report-image

US-Diabetes Drug Market Size & Share - by Type of Diabetes (Type 1 Diabetes, Type 2 Diabetes), by Delivery Method (Insulin-based therapies, Oral medications), by Drug Class (SGLT2 Inhibitors, GLP-1 Receptor Agonists, Insulin, DPP-4 Inhibitors, and Others), By Distribution Channel (Hospital, Retail, Online pharmacies) and by Region: Global Forecast till 2033

  • PUBLISHED ON
  • 2023-12-07
  • NO OF PAGES
  • 214
  • CATEGORY
  • Healthcare & Life Sciences

Market Overview

US-Diabetes Drug Market is projected to achieve a value of USD 29.2 Billion in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 40.32 Billion by 2033 with a CAGR of 3.8% during the forecast period 2024-2033.

Diabetes is a chronic illness that impairs the body's capacity to control glucose, or blood sugar. There are several ways that it manifests, but types 1 and 2 are the most common. Moreover, gestational diabetes increases the risk of type 2 diabetes in both the mother and her unborn child and might appear throughout pregnancy. Diabetes that is not properly controlled can cause heart disease, renal problems, nerve damage, and eye impairments, among other health problems.

 

 

               Get more in-depth information of this reports – Request Free Sample

The US-Diabetes Drug Market is impacted by a number of factors and number of significant variables are contributing to the rising prevalence of diabetes, including an aging population, sedentary lifestyles, bad eating habits, and technological advancements in medication administration. In addition, rising awareness of the need to manage diabetes, along with legislation that encourage reimbursement and pharmaceutical companies' ongoing research and development initiatives, propel market growth. The introduction of new medications that better address unmet patient needs and enhance treatment options—such as US-Diabetes Drugs and GLP-1 receptor agonists—while also providing increased efficacy and fewer side effects, further expands the market.

Market Scope

Report Attributes

Description

Market Size in 2023

USD 29.02 Billion

Market Forecast in 2033

USD 40.32 Billion

CAGR % 2024-2033

3.8%

Base Year

2023

Historic Data

2016-2022

Forecast Period

2024-2033

Report USP

 

Consumption, company share, company heatmap, company production capacity, growth factors and more

Segments Covered

by Type of Diabetes, by Delivery Method, by Drug Class, By Distribution Channel and By Region

Key Growth Drivers

Advances in drug development and the introduction of new technologies, such as continuous glucose monitoring and innovative insulin delivery systems, contribute to the growth of the diabetes drug market.

The trend toward personalized medicine and tailored treatment approaches for diabetes patients contributes to the development of new and targeted drug therapies.

Government initiatives to address chronic diseases, including diabetes, and healthcare policies that promote access to diabetes medications can impact market growth.

Regional Scope

North America

Country Scope

U.S

 

US-Diabetes Drug Industry:  Dynamics & Restrains

Market Drivers

The increasing incidence of diabetes in the US population - The growing prevalence of diabetes among the populace in the US is a significant component fueling the diabetes drug market's expansion for diabetic medications. As more people are diagnosed with diabetes, there is an increasing demand for effective medications to treat this chronic condition. Pharmaceutical R&D is aided by this surge in demand, which produces novel drug cures and treatments. Companies put a lot of effort into developing innovative medications that satisfy a variety of patient needs, which fosters market expansion. The sheer volume of cases that are found means that there is a continuous need for novel therapies, which fosters a dynamic market that may change to meet the ever-changing demands of diabetics.

Changes in lifestyle patterns - Changes in lifestyle have a major impact on the dynamics of the US diabetic medication industry. Diabetes is more common due to sedentary lifestyles, bad eating habits, and rising obesity rates. These modifications to lifestyle fuel the need for novel medications to control and lessen the impact of the illness. In response, pharmaceutical companies create drugs specifically designed to handle the unique problems brought on by these lifestyle-related variables. There is a boom in the market for a variety of pharmaceuticals that emphasize managing complications in addition to glucose control. This is indicative of the shifting landscape that is driven by changing lifestyles and how they affect the management of diabetes.

Market Restrains

Stringent regulatory requirements for drug approval - The US Diabetes Drug Market is severely constrained by strict regulatory requirements for medication approval. The launch of new pharmaceuticals is delayed by these criteria, which lengthen the process of drug development. Extensive trials and data collection are required to meet the strict safety and efficacy criteria, which prolongs the time and cost required for market access. Because of the financial risks involved, some pharmaceutical companies are discouraged from pursuing novel diabetes treatment research due to the tight regulations that often result in greater development costs. As a result, this limits the market's capacity to quickly provide cutting-edge therapeutics to address the rising diabetes burden by impeding the availability of novel treatments.

US-Diabetes Drug Segmentation

Market- By Type of Diabetes Analysis

By Type of Diabetes, the US-Diabetes Drug Market is Categories into Type 1 Diabetes, Type 2 Diabetes. The Type 2 Diabetes segment accounts for the largest share of around 87% in 2022.


Type 2 diabetes is mostly caused by lifestyle factors, such as obesity, unhealthy eating patterns, and sedentary behavior. A higher number of cases of Type 2 diabetes is correlated with rising obesity rates.

The following segments are part of an in-depth analysis of US-Diabetes Drug Market:

Market Segments

 

By Delivery Method

·         Insulin-based therapies

·         Oral medications

By Drug Class

·         SGLT2 Inhibitors

·         GLP-1 Receptor Agonists

·         Insulin

·         DPP-4 Inhibitors

·         Others

By Distribution Channel

·         Hospital

·         Retail

·         Online pharmacies

Would you like this research report to be customized to meet your needs?

The information needed to assist you in making wise business decisions

will be covered by our research team – Customize this report

Pointers Covered

The US Diabetes Drug Market Analysis Report provides a comprehensive analysis of the market. The report discusses market segmentation, DROS, and the product portfolios of the key market player companies in the US industry. It also provides the launch or research of new drugs, moreover advancements in the sector including collaborations, mergers, and acquisitions, as well as the impact of the COVID-19 pandemic on the market. The study also offers insights into market trends and an analysis of industry dynamics.

Competitive Analysis

The US-Diabetes Drug Market is dominated by a few large companies, such as

·         Novo Nordisk

·         Eli Lilly and Company

·         Sanofi

·         AstraZeneca

·         Merck & Co

·         Boehringer Ingelheim

There are some of the key trends that are shaping the competitive landscape of the US-Diabetes Drug Market.

·         November 2022, Tzield (teplizumab-mzwv) injection was licensed by the US Food and Drug Administration to treat adults and pediatric patients 8 years of age and older with stage 2 type 1 diabetes in order to postpone the onset of stage 3 diabetes.

·         May 2022, In addition to diet and exercise, the U.S. Food and Drug Administration has approved the injection of Mounjaro (tirzepatide) to help adults with type 2 diabetes better regulate their blood sugar levels. Clinical tests showed that Mounjaro was superior to other diabetic medications in terms of its ability to lower blood sugar.

1.      US-Diabetes Drug Market Introduction and Market Overview

1.1.   Objectives of the Study

1.2.   US-Diabetes Drug Market Scope and Market Estimation

1.2.1.      US-Diabetes Drug Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2033)

1.2.2.      US-Diabetes Drug Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2033

1.3.   Market Segmentation

1.3.1.      Component of US-Diabetes Drug Market

1.3.2.      Technology of US-Diabetes Drug Market

1.3.3.      Drug Class of US-Diabetes Drug Market

1.3.4.      Region of US-Diabetes Drug Market

2.      Executive Summary

2.1.   US-Diabetes Drug Market Industry Trends under COVID-19 Outbreak

2.1.1.      Global COVID-19 Status Overview

2.1.2.      Influence of COVID-19 Outbreak on US-Diabetes Drug Market Industry Development

2.2.   Market Dynamics

2.2.1.      Drivers

2.2.2.      Limitations

2.2.3.      Opportunities

2.2.4.      Impact Analysis of Drivers and Restraints

2.3.   Pricing Trends Analysis & Average Selling Prices (ASPs)

2.4.   Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.5.   Porter’s Five Forces Analysis

2.5.1.      Bargaining Power of Suppliers

2.5.2.      Bargaining Power of Buyers

2.5.3.      Threat of Substitutes

2.5.4.      Threat of New Entrants

2.5.5.      Competitive Rivalry

2.6.   Value Chain / Ecosystem Analysis

2.7.   Russia-Ukraine War Impacts Analysis

2.8.   Economic Downturn Analysis

2.9.     Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      US-Diabetes Drug Market Estimates & Historical Trend Analysis (2019 - 2022)

4.      US-Diabetes Drug Market Estimates & Forecast Trend Analysis, by TYPE OF DIABETES

4.1.   US-Diabetes Drug Market Revenue (US$ Mn) Estimates and Forecasts, by TYPE OF DIABETES, 2019 to 2033

4.1.1.      Type 1 Diabetes

4.1.2.      Type 2 Diabetes

5.      US-Diabetes Drug Market Estimates & Forecast Trend Analysis, by Delivery Method

5.1.   US-Diabetes Drug Market Revenue (US$ Mn) Estimates and Forecasts, by Delivery Method, 2019 to 2033

5.1.1.      Insulin-based therapies

5.1.2.      Oral medications

6.      US-Diabetes Drug Market Estimates & Forecast Trend Analysis, by Drug Class

6.1.   US-Diabetes Drug Market Revenue (US$ Mn) Estimates and Forecasts, by Drug Class, 2019 to 2033

6.1.1.      SGLT2 Inhibitors

6.1.2.      GLP-1 Receptor Agonists

6.1.3.      Insulin

6.1.4.      DPP-4 Inhibitors

6.1.5.      Others

7.      US-Diabetes Drug Market Estimates & Forecast Trend Analysis, by DISTRIBUTION CHANNEL

7.1.   US-Diabetes Drug Market Revenue (US$ Mn) Estimates and Forecasts, by Drug Class, 2019 to 2033

7.1.1.      Hospital

7.1.2.      Retail

7.1.3.      Online pharmacies

8.      US-Diabetes Drug Market Estimates & Forecast Trend Analysis, by Region

8.1.   US-Diabetes Drug Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2033

8.1.1.      North America

9.      North America Cardiac Biomarkers Market: Estimates & Forecast Trend Analysis

9.1.   North America Cardiac Biomarkers Market Assessments & Key Findings

9.1.1.      North America Cardiac Biomarkers Market Introduction

9.1.2.      North America Cardiac Biomarkers Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

9.1.2.1.  By TYPE OF DIABETES

9.1.2.2.  By Delivery Method

9.1.2.3.  By Drug Class

9.1.2.4.  By DISTRIBUTION CHANNEL

9.1.2.5.  By Country

9.1.2.5.1.   The U.S.

10.  Competition Landscape

10.1. US-Diabetes Drug Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

10.2. US-Diabetes Drug Market Competition White Space Analysis, By Drug Class

10.3. US-Diabetes Drug Market Competition Heat Map Analysis, By Drug Class

10.4. US-Diabetes Drug Market Concentration & Company Market Shares (%) Analysis, 2022

11.  Company Profiles

11.1.                    Novo Nordisk

11.1.1.  Company Overview & Key Stats

11.1.2.  Financial Performance & KPIs

11.1.3.  Product Portfolio

11.1.4.  Business Strategy & Recent Developments

* Similar details would be provided for all the players mentioned below 

11.2.     Eli Lilly and Company

11.3.     Sanofi

11.4.     AstraZeneca

11.5.     Merck & Co

11.6.     Boehringer Ingelheim

12.  Research Methodology

12.1. External Transportations / Databases

12.2. Internal Proprietary Database

12.3. Primary Research

12.4. Secondary Research

12.5. Assumptions

12.6. Limitations

12.7. Report FAQs

13.  Research Findings & Conclusion

 

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process




We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.


Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.

Frequently Asked Questions

What is the market size of US-Diabetes Drug Market in 2022?

US-Diabetes Drug Market was valued at USD 27.31 Billion in 2022.

What is the growth rate for the US-Diabetes Drug Market?

US-Diabetes Drug Market size will increase at approximate CAGR of 3.8% during the forecasted period.

Which are the top companies operating within the US-Diabetes Drug Market?

Major companies operating within the US-Diabetes Drug Market are Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co and Boehringer Ingelheim.

CHOOSE LICENSE TYPE
QLOUD
Pricing

Select a license type that suits your business needs

Single User Access

US $3950

Only Three Thousand Nine Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $4950

Only Four Thousand Nine Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $5950

Only Five Thousand Nine Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI